

REVLIMID REMS® Pharmacy Certification Quiz

1. Authorization numbers for females of reproductive potential are valid for up to \_\_\_\_ days:  
(Mandatory Question)
  - a. **7 days**
  - b. 10 days
  - c. 14 days
  - d. 28 days
  
2. It is not necessary to obtain a confirmation number to dispense. (Mandatory Question)
  - a. True
  - b. **False**
  
3. Celgene REMS programs are mandated to avoid embryo-fetal exposure and to inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for each treatment.  
(Mandatory Question)
  - a. **True**
  - b. False
  
4. It is not required to retain the prescription with the authorization and confirmation numbers for each filled prescription. It is not necessary to complete the Education and Counseling Checklist.
  - a. True
  - b. **False**
  
5. According to the package insert's boxed warnings and warnings and precautions, neutropenia, thrombocytopenia, deep venous thrombosis, and pulmonary embolism as well as risk of myocardial infarction and stroke have been reported in patients receiving REVLIMID.  
(Mandatory Question)
  - a. **True**
  - b. False
  
6. REVLIMID can cause serious birth defects. (Mandatory Question)
  - a. **True**
  - b. False
  
7. What pregnancy precautions are required for a female of reproductive potential with respect to heterosexual sexual contact?
  - a. **Must use at the same time at least 1 highly effective method and at least 1 additional effective method of birth control every time she has sex with a male, beginning at least 4 weeks before therapy, during therapy (including dose interruptions), and for at least 4 weeks after stopping therapy**
  - b. Abstain from having any heterosexual sexual contact only while taking therapy
  - c. After stopping therapy it is okay to get pregnant at any time
  - d. Use 2 forms of birth control 2 weeks before taking therapy

8. What precautions are required for a male with respect to sexual contact with his female partner of reproductive potential?
- Use of a latex or synthetic condom every time he has sexual intercourse with a FRP during therapy (including dose interruptions) and for 4 weeks after stopping therapy, even if he has undergone a successful vasectomy**
  - Abstain from having any sexual contact with a female of reproductive potential only while taking therapy
  - Use latex or synthetic condoms while taking therapy. No precautions are necessary once treatment has stopped
  - Males taking therapy who have had a vasectomy do not need to use latex or synthetic condoms
9. For all Celgene REMS programs, female patients of reproductive potential must have a negative pregnancy test: *(Mandatory Question)*
- Prior to initial prescription
  - Prior to subsequent prescription
  - Prior to initial prescription and prior to subsequent prescription**
  - None of these
10. Adverse drug experiences that are suspected to be associated with the use of therapy, and any suspected pregnancy occurring during treatment, must be reported to Celgene. *(Mandatory Question)*
- True**
  - False
11. The Medication Guide must be provided every time REVLIMID is dispensed. *(Mandatory Question)*
- True**
  - False
12. A certified Celgene REMS pharmacy cannot dispense more than a \_\_\_\_\_ supply of REVLIMID.
- 28 day**
  - 3 month
  - 2 week
  - 1 year
13. Authorization numbers for patient risk categories other than females of reproductive potential are valid for up to \_\_\_\_\_ days. *(Mandatory Question)*
- 30 days**
  - 10 days
  - 7 days
  - 28 days

14. A male patient can donate sperm at any time during therapy.

a. True

b. **False**

6/16

REMS-REV16781